$48m market cap

$0.33 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo continues to make progress in its goal to establish its various subsidiaries as independent businesses. Odor-No-More recorded revenue of $301,000 for Q119 (of $364,000 total), down 10.7% from Q419. It cited lumpiness in its sales pattern caused by the timing of orders, weather and manufacturing, and the fact that approximately 20% ($68,000) of orders were in process at the end of the quarter. This business is expanding with new distribution agreements in the waste handling and cannabis industries. BioLargo Water has placed it first Advanced Oxidation System (AOS) treatment train, and Clyra Medical will run a 30-day animal study to support a 510(k) application for its wound treatment product.

Share price graph
Price performance
Actual 50.1 94.1 10.8
Relative* 45.8 89.1 4.9
52-week high/low US$0.4/US$0.2
*% relative to local index
Key management
Dennis Calvert President & CEO